PL372413A1 - Phosphate prodrugs of fluorooxindoles - Google Patents
Phosphate prodrugs of fluorooxindolesInfo
- Publication number
- PL372413A1 PL372413A1 PL03372413A PL37241303A PL372413A1 PL 372413 A1 PL372413 A1 PL 372413A1 PL 03372413 A PL03372413 A PL 03372413A PL 37241303 A PL37241303 A PL 37241303A PL 372413 A1 PL372413 A1 PL 372413A1
- Authority
- PL
- Poland
- Prior art keywords
- fluorooxindoles
- phosphate prodrugs
- prodrugs
- phosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36601002P | 2002-03-20 | 2002-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL372413A1 true PL372413A1 (en) | 2005-07-25 |
Family
ID=28454740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03372413A PL372413A1 (en) | 2002-03-20 | 2003-03-20 | Phosphate prodrugs of fluorooxindoles |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6930100B2 (enExample) |
| EP (1) | EP1485085A4 (enExample) |
| JP (1) | JP4359150B2 (enExample) |
| KR (1) | KR100951499B1 (enExample) |
| CN (1) | CN100384820C (enExample) |
| BR (1) | BR0308737A (enExample) |
| CA (1) | CA2479256A1 (enExample) |
| CO (1) | CO5611143A2 (enExample) |
| GE (1) | GEP20074230B (enExample) |
| HR (1) | HRP20040853A2 (enExample) |
| IL (2) | IL164022A0 (enExample) |
| IS (1) | IS7456A (enExample) |
| MX (1) | MXPA04008999A (enExample) |
| NO (1) | NO20044442L (enExample) |
| NZ (1) | NZ535365A (enExample) |
| PL (1) | PL372413A1 (enExample) |
| RS (1) | RS81904A (enExample) |
| RU (1) | RU2312857C2 (enExample) |
| UA (1) | UA77296C2 (enExample) |
| WO (1) | WO2003080047A1 (enExample) |
| ZA (1) | ZA200407337B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| US6916937B2 (en) * | 2003-02-03 | 2005-07-12 | Bristol-Myers Squibb Company | Carbohydrate prodrugs of fluorooxindoles |
| US8178671B2 (en) | 2003-07-30 | 2012-05-15 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds |
| US7169803B2 (en) * | 2004-03-15 | 2007-01-30 | Bristol-Myers Squibb Company | N-substituted prodrugs of fluorooxindoles |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| EP1856135B1 (en) | 2005-01-19 | 2009-12-09 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| US8227455B2 (en) * | 2005-04-18 | 2012-07-24 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders |
| WO2007032263A1 (ja) * | 2005-09-13 | 2007-03-22 | Eisai R & D Management Co., Ltd. | 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法 |
| TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
| TW200841879A (en) | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
| US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
| WO2009100090A1 (en) * | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| US8188119B2 (en) | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
| HRP20171415T4 (hr) | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
| WO2010151711A1 (en) * | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
| WO2011163594A2 (en) * | 2010-06-24 | 2011-12-29 | Alkermes, Inc. | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
| SG11201702041PA (en) | 2015-07-06 | 2017-04-27 | Gilead Sciences Inc | Cot modulators and methods of use thereof |
| PE20211305A1 (es) | 2018-01-05 | 2021-07-20 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas |
| CN112218867B (zh) * | 2018-03-05 | 2023-11-21 | 泰昂治疗公司 | 腺苷受体拮抗剂及其用途 |
| AU2019230014B2 (en) | 2018-03-05 | 2024-11-28 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CR20220058A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos |
| CR20220057A (es) | 2019-07-10 | 2022-07-19 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos |
| CN115397511A (zh) | 2020-03-30 | 2022-11-25 | 吉利德科学公司 | Cot抑制剂化合物(s)-6-(((1-(双环[1.1.1]戊-1-基)-1h-1,2,3-三唑-4-基)2-甲基-1-氧代-1,2-二氢异喹啉-5-基)甲基)))氨基8-氯-(新戊基氨基)喹啉-3-甲腈的固体形式 |
| US11845737B2 (en) | 2020-04-02 | 2023-12-19 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
| EP3912625A1 (en) | 2020-05-20 | 2021-11-24 | Kaerus Bioscience Limited | Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders |
| WO2025233532A1 (en) | 2024-05-10 | 2025-11-13 | Les Laboratoires Servier | Maxi-k potassium channel openers and therapeutic applications thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU749063A1 (ru) * | 1979-01-29 | 1996-09-10 | Военно-медицинская академия им.С.М.Кирова | 3-(4-карбэтокси)-фенилимино-2-оксоиндолин, повышающий устойчивость организма к повторной черепно-мозговой травме |
| US5234947A (en) | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
| US5187173A (en) * | 1991-12-27 | 1993-02-16 | Sterling Winthrop Inc. | 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof |
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| CA2317008C (en) | 1997-12-31 | 2009-01-20 | The University Of Kansas | Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof |
| CA2318817A1 (en) * | 1998-01-29 | 1999-08-05 | Bristol-Myers Squibb Company | Phosphate derivatives of diaryl 1,3,4-oxadiazolone |
-
2003
- 2003-03-20 PL PL03372413A patent/PL372413A1/xx not_active Application Discontinuation
- 2003-03-20 RU RU2004131201/04A patent/RU2312857C2/ru not_active IP Right Cessation
- 2003-03-20 MX MXPA04008999A patent/MXPA04008999A/es active IP Right Grant
- 2003-03-20 WO PCT/US2003/008613 patent/WO2003080047A1/en not_active Ceased
- 2003-03-20 UA UA20041109513A patent/UA77296C2/uk unknown
- 2003-03-20 NZ NZ535365A patent/NZ535365A/en not_active IP Right Cessation
- 2003-03-20 CN CNB038109778A patent/CN100384820C/zh not_active Expired - Fee Related
- 2003-03-20 JP JP2003577875A patent/JP4359150B2/ja not_active Expired - Fee Related
- 2003-03-20 BR BR0308737-9A patent/BR0308737A/pt not_active IP Right Cessation
- 2003-03-20 CA CA002479256A patent/CA2479256A1/en not_active Abandoned
- 2003-03-20 RS YUP-819/04A patent/RS81904A/sr unknown
- 2003-03-20 HR HRP20040853 patent/HRP20040853A2/xx not_active Application Discontinuation
- 2003-03-20 EP EP03711659A patent/EP1485085A4/en not_active Withdrawn
- 2003-03-20 KR KR1020047014626A patent/KR100951499B1/ko not_active Expired - Fee Related
- 2003-03-20 US US10/393,031 patent/US6930100B2/en not_active Expired - Lifetime
- 2003-03-20 IL IL16402203A patent/IL164022A0/xx active IP Right Grant
- 2003-03-20 GE GEAP8458A patent/GEP20074230B/en unknown
-
2004
- 2004-09-12 IL IL164022A patent/IL164022A/en not_active IP Right Cessation
- 2004-09-13 ZA ZA200407337A patent/ZA200407337B/en unknown
- 2004-09-17 IS IS7456A patent/IS7456A/is unknown
- 2004-09-20 CO CO04093294A patent/CO5611143A2/es not_active Application Discontinuation
- 2004-10-19 NO NO20044442A patent/NO20044442L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20030195169A1 (en) | 2003-10-16 |
| EP1485085A4 (en) | 2007-03-14 |
| KR20040106293A (ko) | 2004-12-17 |
| IS7456A (is) | 2004-09-17 |
| NZ535365A (en) | 2006-07-28 |
| CN1652769A (zh) | 2005-08-10 |
| EP1485085A1 (en) | 2004-12-15 |
| BR0308737A (pt) | 2005-01-11 |
| RS81904A (sr) | 2007-02-05 |
| WO2003080047A1 (en) | 2003-10-02 |
| JP2005526097A (ja) | 2005-09-02 |
| CN100384820C (zh) | 2008-04-30 |
| JP4359150B2 (ja) | 2009-11-04 |
| IL164022A0 (en) | 2005-12-18 |
| RU2004131201A (ru) | 2005-05-10 |
| GEP20074230B (en) | 2007-11-12 |
| CA2479256A1 (en) | 2003-10-02 |
| RU2312857C2 (ru) | 2007-12-20 |
| UA77296C2 (en) | 2006-11-15 |
| HRP20040853A2 (en) | 2004-12-31 |
| CO5611143A2 (es) | 2006-02-28 |
| MXPA04008999A (es) | 2004-12-07 |
| US6930100B2 (en) | 2005-08-16 |
| IL164022A (en) | 2008-04-13 |
| ZA200407337B (en) | 2006-02-22 |
| AU2003215017A1 (en) | 2003-10-08 |
| KR100951499B1 (ko) | 2010-04-07 |
| NO20044442L (no) | 2004-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040853A2 (en) | Phosphate prodrugs of fluorooxindoles | |
| PL371526A1 (en) | Phosphorus-containing compounds and uses thereof | |
| IL212689A0 (en) | Prodrugs of 9 - aminomethyl tetracycline compounds | |
| EG23458A (en) | Set of elements for assemlying structures | |
| AU2003211052A1 (en) | Phospholipids as caspase inhibitor prodrugs | |
| EP1549316A4 (en) | HAMMER OF TFGbeta | |
| AU2003236991A8 (en) | Representations of processes | |
| EP1511488A4 (en) | HUMAN INHIBITORS OF ADAM 10 | |
| AU2003287605A8 (en) | Polymeric prodrugs of vancomycin | |
| IL165475A0 (en) | Nitrooxyderivatives of eyclooxygenase-2 inhibitors | |
| AU148927S (en) | Section of an orthotic insert | |
| AU2003215796A8 (en) | Audio distribution | |
| AU148928S (en) | Section of an orthotic insert | |
| AU2003245627A8 (en) | Kinases and phosphatases | |
| AU2003288237A1 (en) | Artificial esterases | |
| IL162158A (en) | Prodrugs to d-prolines | |
| AU2003287427A8 (en) | Kinases and phosphatases | |
| AU2003304244A8 (en) | Epoxy-stabilized polyphosphate compositions | |
| HK1067074A (en) | Phosphate prodrugs of fluorooxindoles | |
| AU2003231531A8 (en) | Kinases and phosphatases | |
| GB0223783D0 (en) | Didgeridoo manufacture | |
| AU2003240435A8 (en) | Pna prodrugs | |
| GB2393207B (en) | Means of assembly | |
| GB2388512B (en) | Management of forests | |
| IL152163A0 (en) | Watersoluble prodrugs of propofol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |